Psihogios Alexandra M, El-Khatib Ayah, Matos Kevin, Rabbi Mashfiqui, Rossoff Jenna, Dinner Shira, Zeng Kristy, Picos Raymundo, Ahmed Annisa, Patel Esha M, Fleisher Linda, Hunger Stephen P, Pai Ahna, Laurenceau Jean-Philippe, Rini Christine, Barakat Lamia P, Schwartz Lisa A, Murphy Susan, Yanez Betina
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA.
Pediatr Blood Cancer. 2025 Aug;72(8):e31756. doi: 10.1002/pbc.31756. Epub 2025 May 9.
Acute lymphoblastic leukemia/lymphoma therapy includes a maintenance phase involving daily administration of an oral chemotherapy called 6-mercaptopurine (6-MP). Adolescents and young adults (AYAs) exhibit lower 6-MP adherence than younger patients, which increases their relapse risk. However, effective oral chemotherapy adherence interventions for this AYA population are lacking.
This study describes the human-centered design process of co-creating ADAPTS, an app-based just-in-time adaptive intervention for 6-MP adherence in AYAs.
Across three design waves with input from AYAs (n = 19) and their caregivers (n = 14), we conducted interviews to co-develop and refine ADAPTS. Qualitative data were coded using conventional content analysis to identify themes that informed app design.
Four design priorities for an oral chemotherapy adherence digital intervention were identified: (i) personalize messages to the contextual factors that fluctuate and impact adherence, such as symptoms and mood; (ii) enhance the persuasiveness of adherence messages by framing them positively (e.g., a focus on maintaining remission rather than preventing a relapse), and including the perspectives of peers in popular social media formats; (iii) include customizable app features and the ability to track personal adherence progress; and (iv) facilitate dyadic adherence communication between AYAs and their caregivers, who are often involved.
By developing ADAPTS with AYAs and their caregivers, this digital health intervention offers a novel and patient-centric approach to enhancing adherence. The resulting design priorities and human-centered design methods employed have generalizable potential for addressing other AYA cancer health behaviors.
急性淋巴细胞白血病/淋巴瘤治疗包括一个维持阶段,涉及每日口服一种名为6-巯基嘌呤(6-MP)的化疗药物。青少年和青年(AYA)患者的6-MP依从性低于较年轻患者,这增加了他们的复发风险。然而,针对这一AYA人群缺乏有效的口服化疗依从性干预措施。
本研究描述了共同创建ADAPTS的以人为主导的设计过程,ADAPTS是一款基于应用程序的即时自适应干预措施,用于提高AYA患者对6-MP的依从性。
在来自AYA患者(n = 19)及其护理人员(n = 14)的意见参与下,历经三个设计阶段,我们进行了访谈以共同开发和完善ADAPTS。使用传统内容分析法对定性数据进行编码,以确定为应用程序设计提供信息的主题。
确定了口服化疗依从性数字干预的四个设计重点:(i)根据波动并影响依从性的情境因素(如症状和情绪)个性化信息;(ii)通过积极构建依从性信息(如专注于维持缓解而非预防复发)并在流行社交媒体形式中纳入同伴观点来增强信息的说服力;(iii)包括可定制的应用程序功能以及跟踪个人依从性进展的能力;(iv)促进AYA患者与其通常参与其中的护理人员之间的二元依从性沟通。
通过与AYA患者及其护理人员共同开发ADAPTS,这种数字健康干预措施提供了一种新颖且以患者为中心的提高依从性的方法。所产生的设计重点和采用的以人为主导的设计方法在解决其他AYA癌症健康行为方面具有可推广的潜力。